As of Oct 21
| -0.02 / -0.04%|
The 9 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 66.00, with a high estimate of 96.00 and a low estimate of 60.00. The median estimate represents a +44.58% increase from the last price of 45.65.
The current consensus among 10 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.